Literature DB >> 2439401

Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy.

P S Sharp, T J Fallon, O J Brazier, L Sandler, G F Joplin, E M Kohner.   

Abstract

Between 1960 and 1976 117 patients underwent pituitary implantation with yttrium-90 (90Y) for treatment of proliferative retinopathy at the Hammersmith Hospital, London. Mean age at operation was 35 +/- 11 years (mean +/- SD), and mean duration of diabetes 18.6 +/- 10.0 years. Mean insulin dosage prior to implant was 67.2 +/- 24 units, falling to 30.4 +/- 14.9 units post-implant. Thirty-two per cent of patients are still living, 60% are deceased and 8% are lost to follow-up. The 5-year survival rate was 82%. Of the causes of death, 21% died of infection, adrenal insufficiency or hypoglycaemia, 12% of renal failure, and 47% of myocardial or cerebral vascular disease. Ophthalmological follow-up was carried out on the 100 patients operated on between 1965 and 1976. The mean age of this group at implant was 35 +/- 10.5 years, and mean duration of diabetes 17.2 +/- 8.7 years. Visual acuity in the better eye at operation was 6/12 or better in 84% of patients, and this percentage remained similar at the time of the 5 and 10 year follow-up. Blindness (6/60 or worse) in both eyes was present in 12% of patients at the time of 5 and 10 year assessments. By 5 years new vessels on the disc had improved from a mean grading of 2.7 +/- 1.6 to 0.8 +/- 1.2 (p less than 0.001), and by 10 years there was no disc neovascularisation in any eye. There was a similar improvement in the grading of hard exudates, microaneurysms and haemorrhages, but there was an increase in fibrous retinitis proliferans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439401     DOI: 10.1007/bf00270416

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  30 in total

Review 1.  PITUITARY ABLATION IN THE TREATMENT OF DIABETIC RETINOPATHY.

Authors:  R F BRADLEY; S B REES; C A FAGER
Journal:  Med Clin North Am       Date:  1965-07       Impact factor: 5.456

2.  Needle implantation of yttrium seeds for pituitary ablation in cases of secondary carcinoma.

Authors:  R FRASER; J W LAWS; G F JOPLIN; R MORRISON; R E STEINER
Journal:  Lancet       Date:  1959-02-21       Impact factor: 79.321

3.  Effect of pituitary ablation on the renal arteriolar and glomerular lesions in diabetes.

Authors:  J T Ireland; B K Patnaik; L J Duncan
Journal:  Diabetes       Date:  1967-09       Impact factor: 9.461

4.  Diabetic retinopathy: new vessels arising from the optic disc. I. Grading system and natural history.

Authors:  E M Kohner; A Panisset; H Cheng; T R Fraser
Journal:  Diabetes       Date:  1971-12       Impact factor: 9.461

5.  Long-term effects of transsphenoidal hypophysectomy on growth hormone, renal function and eyeground in patients with diabetic retinopathy.

Authors:  A Teuscher; F Escher; H König; G Zahnd
Journal:  Diabetes       Date:  1970-07       Impact factor: 9.461

6.  Effect of pituitary ablation on diabetic retinopathy studied by fluorescence angiography.

Authors:  E M Kohner; C T Dollery; T R Fraser; C J Bulpitt
Journal:  Diabetes       Date:  1970-10       Impact factor: 9.461

7.  Pituitary ablation for diabetic retinopathy.

Authors:  G F Joplin; R Fraser; D W Hill; N W Oakley; D J Scott
Journal:  Q J Med       Date:  1965-10

8.  Prognosis of proliferative retinopathy in juvenile diabetics.

Authors:  T Deckert; S E Simonsen; J E Poulsen
Journal:  Diabetes       Date:  1967-10       Impact factor: 9.461

9.  Diabetes, diabetic angiopathy, and growth hormone.

Authors:  K Lundbaek; N J Christensen; V A Jensen; K Johansen; T S Olsen; A P Hansen; H Orskov; R Osterby
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

10.  Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood.

Authors:  S M Shalet; C G Beardwell; I A MacFarlane; P H Jones; D Pearson
Journal:  Acta Endocrinol (Copenh)       Date:  1977-04
View more
  7 in total

1.  Somatostatin and diabetic retinopathy: an evolving story.

Authors:  Olga Simó-Servat; Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2018-02-20       Impact factor: 3.633

Review 2.  Diabetic retinopathy.

Authors:  E M Kohner
Journal:  BMJ       Date:  1993-11-06

3.  Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro.

Authors:  Z Rymaszewski; R M Cohen; P Chomczynski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

4.  Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy.

Authors:  E Chantelau
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

5.  Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years.

Authors:  Patrizio Tatti; Patrizia Di Mauro; Leonardo Masselli; Adriano Longobardi; Annabel Barber
Journal:  Clin Ophthalmol       Date:  2010-11-15

6.  Response: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404).

Authors:  Sang Youl Rhee; Jeong Taek Woo
Journal:  Diabetes Metab J       Date:  2017-12       Impact factor: 5.376

7.  Association of IGF1 with glycemic control and occurrence of severe hypoglycemia in patients with type 1 diabetes mellitus.

Authors:  Louise Færch; Anders Juul; Ulrik Pedersen-Bjergaard; Birger Thorsteinsson
Journal:  Endocr Connect       Date:  2012-06-21       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.